In­cyte tries to fend off TR­C's mi­ni-ten­der of­fer to in­vestors; Grit­stone On­col­o­gy scoops Acte­lion CFO Jean-Marc Bellemin

→ In­cyte $IN­CY is count­ing on its in­vestors to pro­tect 0.71% — or 1,500,000 shares — of its com­mon stock, from Cana­da’s TRC Cap­i­tal, which is out to buy them at a dis­count price. The in­vest­ment firm promised $88.88 per share in cash, com­pared to $93.16 that In­cyte said it was trad­ing at when the of­fer com­menced. The Wilm­ing­ton, DL com­pa­ny notes that TRC has made “many sim­i­lar un­so­licit­ed mi­ni-ten­der of­fers” for oth­er pub­lic com­pa­nies’ shares, and urge share­hold­ers to ig­nore or with­draw from the trans­ac­tion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER